Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135672238> ?p ?o ?g. }
- W2135672238 endingPage "489" @default.
- W2135672238 startingPage "489" @default.
- W2135672238 abstract "Gamma-aminobutyric acid receptor agonist medications are the most commonly used sedatives for intensive care unit (ICU) patients, yet preliminary evidence indicates that the alpha(2) agonist dexmedetomidine may have distinct advantages.To compare the efficacy and safety of prolonged sedation with dexmedetomidine vs midazolam for mechanically ventilated patients.Prospective, double-blind, randomized trial conducted in 68 centers in 5 countries between March 2005 and August 2007 among 375 medical/surgical ICU patients with expected mechanical ventilation for more than 24 hours. Sedation level and delirium were assessed using the Richmond Agitation-Sedation Scale (RASS) and the Confusion Assessment Method for the ICU.Dexmedetomidine (0.2-1.4 microg/kg per hour [n = 244]) or midazolam (0.02-0.1 mg/kg per hour [n = 122]) titrated to achieve light sedation (RASS scores between -2 and +1) from enrollment until extubation or 30 days.Percentage of time within target RASS range. Secondary end points included prevalence and duration of delirium, use of fentanyl and open-label midazolam, and nursing assessments. Additional outcomes included duration of mechanical ventilation, ICU length of stay, and adverse events.There was no difference in percentage of time within the target RASS range (77.3% for dexmedetomidine group vs 75.1% for midazolam group; difference, 2.2% [95% confidence interval {CI}, -3.2% to 7.5%]; P = .18). The prevalence of delirium during treatment was 54% (n = 132/244) in dexmedetomidine-treated patients vs 76.6% (n = 93/122) in midazolam-treated patients (difference, 22.6% [95% CI, 14% to 33%]; P < .001). Median time to extubation was 1.9 days shorter in dexmedetomidine-treated patients (3.7 days [95% CI, 3.1 to 4.0] vs 5.6 days [95% CI, 4.6 to 5.9]; P = .01), and ICU length of stay was similar (5.9 days [95% CI, 5.7 to 7.0] vs 7.6 days [95% CI, 6.7 to 8.6]; P = .24). Dexmedetomidine-treated patients were more likely to develop bradycardia (42.2% [103/244] vs 18.9% [23/122]; P < .001), with a nonsignificant increase in the proportion requiring treatment (4.9% [12/244] vs 0.8% [1/122]; P = .07), but had a lower likelihood of tachycardia (25.4% [62/244] vs 44.3% [54/122]; P < .001) or hypertension requiring treatment (18.9% [46/244] vs 29.5% [36/122]; P = .02).There was no difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients. At comparable sedation levels, dexmedetomidine-treated patients spent less time on the ventilator, experienced less delirium, and developed less tachycardia and hypertension. The most notable adverse effect of dexmedetomidine was bradycardia.clinicaltrials.gov Identifier: NCT00216190 Published online February 2, 2009 (doi:10.1001/jama.2009.56)." @default.
- W2135672238 created "2016-06-24" @default.
- W2135672238 creator A5007527928 @default.
- W2135672238 creator A5015518427 @default.
- W2135672238 creator A5016719143 @default.
- W2135672238 creator A5025258021 @default.
- W2135672238 creator A5036150083 @default.
- W2135672238 creator A5050271902 @default.
- W2135672238 creator A5050629739 @default.
- W2135672238 creator A5064949379 @default.
- W2135672238 creator A5069349916 @default.
- W2135672238 creator A5074852854 @default.
- W2135672238 creator A5085954949 @default.
- W2135672238 date "2009-02-04" @default.
- W2135672238 modified "2023-10-13" @default.
- W2135672238 title "Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients<subtitle>A Randomized Trial</subtitle>" @default.
- W2135672238 cites W147537481 @default.
- W2135672238 cites W1750894135 @default.
- W2135672238 cites W1972422132 @default.
- W2135672238 cites W1982048617 @default.
- W2135672238 cites W1984126430 @default.
- W2135672238 cites W1984152908 @default.
- W2135672238 cites W1995955106 @default.
- W2135672238 cites W2008457702 @default.
- W2135672238 cites W2010316218 @default.
- W2135672238 cites W2011760419 @default.
- W2135672238 cites W2017573472 @default.
- W2135672238 cites W2020891266 @default.
- W2135672238 cites W2025829561 @default.
- W2135672238 cites W2037614372 @default.
- W2135672238 cites W2039728795 @default.
- W2135672238 cites W2042083863 @default.
- W2135672238 cites W2042602590 @default.
- W2135672238 cites W2055028830 @default.
- W2135672238 cites W2059069143 @default.
- W2135672238 cites W2071551212 @default.
- W2135672238 cites W2082311304 @default.
- W2135672238 cites W2085445508 @default.
- W2135672238 cites W2086483570 @default.
- W2135672238 cites W2107748138 @default.
- W2135672238 cites W2112755225 @default.
- W2135672238 cites W2114262384 @default.
- W2135672238 cites W2115415903 @default.
- W2135672238 cites W2123098876 @default.
- W2135672238 cites W2123360196 @default.
- W2135672238 cites W2127031087 @default.
- W2135672238 cites W2132799806 @default.
- W2135672238 cites W2134210134 @default.
- W2135672238 cites W2138021422 @default.
- W2135672238 cites W2138141660 @default.
- W2135672238 cites W2145816995 @default.
- W2135672238 cites W2159138643 @default.
- W2135672238 cites W2160359556 @default.
- W2135672238 cites W2166663793 @default.
- W2135672238 cites W2171351308 @default.
- W2135672238 cites W2322121630 @default.
- W2135672238 cites W2322707526 @default.
- W2135672238 cites W2768146862 @default.
- W2135672238 cites W2107978811 @default.
- W2135672238 doi "https://doi.org/10.1001/jama.2009.56" @default.
- W2135672238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19188334" @default.
- W2135672238 hasPublicationYear "2009" @default.
- W2135672238 type Work @default.
- W2135672238 sameAs 2135672238 @default.
- W2135672238 citedByCount "1390" @default.
- W2135672238 countsByYear W21356722382012 @default.
- W2135672238 countsByYear W21356722382013 @default.
- W2135672238 countsByYear W21356722382014 @default.
- W2135672238 countsByYear W21356722382015 @default.
- W2135672238 countsByYear W21356722382016 @default.
- W2135672238 countsByYear W21356722382017 @default.
- W2135672238 countsByYear W21356722382018 @default.
- W2135672238 countsByYear W21356722382019 @default.
- W2135672238 countsByYear W21356722382020 @default.
- W2135672238 countsByYear W21356722382021 @default.
- W2135672238 countsByYear W21356722382022 @default.
- W2135672238 countsByYear W21356722382023 @default.
- W2135672238 crossrefType "journal-article" @default.
- W2135672238 hasAuthorship W2135672238A5007527928 @default.
- W2135672238 hasAuthorship W2135672238A5015518427 @default.
- W2135672238 hasAuthorship W2135672238A5016719143 @default.
- W2135672238 hasAuthorship W2135672238A5025258021 @default.
- W2135672238 hasAuthorship W2135672238A5036150083 @default.
- W2135672238 hasAuthorship W2135672238A5050271902 @default.
- W2135672238 hasAuthorship W2135672238A5050629739 @default.
- W2135672238 hasAuthorship W2135672238A5064949379 @default.
- W2135672238 hasAuthorship W2135672238A5069349916 @default.
- W2135672238 hasAuthorship W2135672238A5074852854 @default.
- W2135672238 hasAuthorship W2135672238A5085954949 @default.
- W2135672238 hasConcept C126322002 @default.
- W2135672238 hasConcept C141071460 @default.
- W2135672238 hasConcept C168563851 @default.
- W2135672238 hasConcept C177713679 @default.
- W2135672238 hasConcept C2776153860 @default.
- W2135672238 hasConcept C2776277131 @default.
- W2135672238 hasConcept C2776376669 @default.
- W2135672238 hasConcept C2776814716 @default.
- W2135672238 hasConcept C2777080012 @default.